Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Trastuzumab Deruxtecan for HER2+ Breast Cancer

February 17th 2018

HER2-Targeted Therapy for HER2 Low-Expressing Breast Cancer

February 17th 2018

Adjuvant Therapy for HER2+ Breast Cancer

February 17th 2018

Refining Neoadjuvant Chemotherapy for HER2+ Breast Cancer

February 17th 2018

Ovarian Suppression in Metastatic HR+ Breast Cancer

February 17th 2018

Neoadjuvant Therapy for HR+ Breast Cancer

February 17th 2018

The Role of Fulvestrant in HR+ Breast Cancer

February 17th 2018

Abemaciclib for HR-Positive Metastatic Breast Cancer

February 17th 2018

Quality of Life for Women with HR-Positive Breast Cancer

February 17th 2018

MONALEESA-7 Trial in Premenopausal HR+ Breast Cancer

February 17th 2018

Dr. Bardia on the Role of the Microenvironment in TNBC

February 17th 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses the role of the microenvironment in the treatment of metastatic triple-negative breast cancer (TNBC).

Findings Support Nab-Paclitaxel as Top Choice for First-Line TNBC Therapy

February 16th 2018

Hope S. Rugo, MD, discusses the importance of individualizing doses of nab-paclitaxel in triple-negative breast cancer.

Dr. Francis on Ovarian Suppression in Young Women With Breast Cancer

February 15th 2018

Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses ovarian suppression in young women with hormone receptor (HR)-positive breast cancer.

Other Promising Targets in TNBC

February 15th 2018

Role of the Androgen Receptor in TNBC

February 15th 2018

Combination Therapy for TNBC: Checkpoint Inhibitor + Chemotherapy

February 15th 2018

Checkpoint Inhibitor Monotherapy for TNBC

February 15th 2018

Antibody-Drug Conjugates in Treating TNBC

February 15th 2018

Paclitaxel vs Nab-Paclitaxel in Metastatic TNBC

February 15th 2018

No pCR in Patients After Neoadjuvant Chemotherapy in TNBC

February 15th 2018